-
1
-
-
84859551467
-
Predictors of mortality in Staphylococcus aureus Bacteremia
-
22491776
-
S.J.van Hal, S.O.Jensen, V.L.Vaska, B.A.Espedido, D.L.Paterson, I.B.Gosbell. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev 2012; 25:362-86; PMID:22491776; http://dx.doi.org/10.1128/CMR.05022-11
-
(2012)
Clin Microbiol Rev
, vol.25
, pp. 362-386
-
-
van Hal, S.J.1
Jensen, S.O.2
Vaska, V.L.3
Espedido, B.A.4
Paterson, D.L.5
Gosbell, I.B.6
-
2
-
-
70349226821
-
Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era
-
19729844
-
F.R.DeLeo, H.F.Chambers. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest 2009; 119:2464-74; PMID:19729844; http://dx.doi.org/10.1172/JCI38226
-
(2009)
J Clin Invest
, vol.119
, pp. 2464-2474
-
-
DeLeo, F.R.1
Chambers, H.F.2
-
3
-
-
84900418033
-
Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study
-
24762631
-
I.Youngster, J.Sauk, C.Pindar, R.G.Wilson, J.L.Kaplan, M.B.Smith, E.J.Alm, D.Gevers, G.H.Russell, E.L.Hohmann. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors:a randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58:1515-22; PMID:24762631; http://dx.doi.org/10.1093/cid/ciu135
-
(2014)
Clin Infect Dis
, vol.58
, pp. 1515-1522
-
-
Youngster, I.1
Sauk, J.2
Pindar, C.3
Wilson, R.G.4
Kaplan, J.L.5
Smith, M.B.6
Alm, E.J.7
Gevers, D.8
Russell, G.H.9
Hohmann, E.L.10
-
4
-
-
79951852718
-
Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus?
-
21297670
-
G.E.Thwaites, V.Gant. Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus? Nat Rev Microbiol 2011; 9:215-22; PMID:21297670; http://dx.doi.org/10.1038/nrmicro2508
-
(2011)
Nat Rev Microbiol
, vol.9
, pp. 215-222
-
-
Thwaites, G.E.1
Gant, V.2
-
5
-
-
84947751820
-
Novel antibody-antibiotic conjugate eliminates intracellular S. aureus
-
26536114
-
S.M.Lehar, T.Pillow, M.Xu, L.Staben, K.K.Kajihara, R.Vandlen, L.DePalatis, H.Raab, W.L.Hazenbos, J.Hiroshi Morisaki, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature 2015; PMID:26536114; http://dx.doi.org/10.1038/nature16057
-
(2015)
Nature
-
-
Lehar, S.M.1
Pillow, T.2
Xu, M.3
Staben, L.4
Kajihara, K.K.5
Vandlen, R.6
DePalatis, L.7
Raab, H.8
Hazenbos, W.L.9
Hiroshi Morisaki, J.10
-
6
-
-
84992705046
-
-
Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC)
-
C.L.S.Zhou, J.Gutierrez, C.Rosenberger, N.Ljumanovic, A.Baruch, M.Carrasco, O.Saad, S.Mariathasan, A.Kamath. Thiomab Antibiotic Conjugate (TAC):PKPD of a novel platform for invasive staphylococcus aureus infections. Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) 2015
-
(2015)
Thiomab Antibiotic Conjugate (TAC): PKPD of a novel platform for invasive staphylococcus aureus infections
-
-
Zhou, C.L.S.1
Gutierrez, J.2
Rosenberger, C.3
Ljumanovic, N.4
Baruch, A.5
Carrasco, M.6
Saad, O.7
Mariathasan, S.8
Kamath, A.9
-
7
-
-
84863012529
-
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
-
22267010
-
B.Q.Shen, K.Xu, L.Liu, H.Raab, S.Bhakta, M.Kenrick, K.L.Parsons-Reponte, J.Tien, S.F.Yu, E.Mai, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012; 30:184-9; PMID:22267010; http://dx.doi.org/10.1038/nbt.2108
-
(2012)
Nat Biotechnol
, vol.30
, pp. 184-189
-
-
Shen, B.Q.1
Xu, K.2
Liu, L.3
Raab, H.4
Bhakta, S.5
Kenrick, M.6
Parsons-Reponte, K.L.7
Tien, J.8
Yu, S.F.9
Mai, E.10
-
8
-
-
84872957381
-
Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
-
23330562
-
S.Kaur, K.Xu, O.M.Saad, R.C.Dere, M.Carrasco-Triguero. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 2013; 5:201-26; PMID:23330562; http://dx.doi.org/10.4155/bio.12.299
-
(2013)
Bioanalysis
, vol.5
, pp. 201-226
-
-
Kaur, S.1
Xu, K.2
Saad, O.M.3
Dere, R.C.4
Carrasco-Triguero, M.5
-
9
-
-
84877245142
-
Bioanalysis of antibody-drug conjugates: American association of pharmaceutical scientists antibody-drug conjugate working group position paper
-
23641692
-
B.Gorovits, S.C.Alley, S.Bilic, B.Booth, S.Kaur, P.Oldfield, S.Purushothama, C.Rao, S.Shord, P.Siguenza. Bioanalysis of antibody-drug conjugates:American association of pharmaceutical scientists antibody-drug conjugate working group position paper. Bioanalysis 2013; 5:997-1006; PMID:23641692; http://dx.doi.org/10.4155/bio.13.38
-
(2013)
Bioanalysis
, vol.5
, pp. 997-1006
-
-
Gorovits, B.1
Alley, S.C.2
Bilic, S.3
Booth, B.4
Kaur, S.5
Oldfield, P.6
Purushothama, S.7
Rao, C.8
Shord, S.9
Siguenza, P.10
-
10
-
-
84856120429
-
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
-
22248267
-
R.Deng, F.Jin, S.Prabhu, S.Iyer. Monoclonal antibodies:what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 2012; 8:141-60; PMID:22248267; http://dx.doi.org/10.1517/17425255.2012.643868
-
(2012)
Expert Opin Drug Metab Toxicol
, vol.8
, pp. 141-160
-
-
Deng, R.1
Jin, F.2
Prabhu, S.3
Iyer, S.4
-
11
-
-
78651400009
-
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?
-
20962582
-
R.Deng, S.Iyer, F.P.Theil, D.L.Mortensen, P.J.Fielder, S.Prabhu. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data:what have we learned? MAbs 2011; 3:61-6; PMID:20962582; http://dx.doi.org/10.4161/mabs.3.1.13799
-
(2011)
MAbs
, vol.3
, pp. 61-66
-
-
Deng, R.1
Iyer, S.2
Theil, F.P.3
Mortensen, D.L.4
Fielder, P.J.5
Prabhu, S.6
-
12
-
-
49449087300
-
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
-
18641636
-
J.R.Junutula, H.Raab, S.Clark, S.Bhakta, D.D.Leipold, S.Weir, Y.Chen, M.Simpson, S.P.Tsai, M.S.Dennis, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26:925-32; PMID:18641636; http://dx.doi.org/10.1038/nbt.1480
-
(2008)
Nat Biotechnol
, vol.26
, pp. 925-932
-
-
Junutula, J.R.1
Raab, H.2
Clark, S.3
Bhakta, S.4
Leipold, D.D.5
Weir, S.6
Chen, Y.7
Simpson, M.8
Tsai, S.P.9
Dennis, M.S.10
-
13
-
-
77951627865
-
Generation and characterization of monoclonal antibody against HSD11B1
-
18177616
-
W.Wang, J.J.Yang, L.Liu, Z.C.Chen, Y.Gao, J.E.Gao, L.G.An, Q.H.Sun. Generation and characterization of monoclonal antibody against HSD11B1. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2008; 24:38-40; PMID:18177616
-
(2008)
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
, vol.24
, pp. 38-40
-
-
Wang, W.1
Yang, J.J.2
Liu, L.3
Chen, Z.C.4
Gao, Y.5
Gao, J.E.6
An, L.G.7
Sun, Q.H.8
-
14
-
-
80052008224
-
Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences
-
21610128
-
W.Wang, P.Lu, Y.Fang, L.Hamuro, T.Pittman, B.Carr, J.Hochman, T.Prueksaritanont. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011; 39:1469-77; PMID:21610128; http://dx.doi.org/10.1124/dmd.111.039453
-
(2011)
Drug Metab Dispos
, vol.39
, pp. 1469-1477
-
-
Wang, W.1
Lu, P.2
Fang, Y.3
Hamuro, L.4
Pittman, T.5
Carr, B.6
Hochman, J.7
Prueksaritanont, T.8
-
15
-
-
84934926662
-
Mechanism-based pharmacokinetic/pharmacodynamic model for Thiomab drug conjugates
-
25446772
-
S.Sukumaran, K.Gadkar, C.Zhang, S.Bhakta, L.Liu, K.Xu, H.Raab, S.F.Yu, E.Mai, A.Fourie-O'Donohue, et al. Mechanism-based pharmacokinetic/pharmacodynamic model for Thiomab drug conjugates. Pharm Res 2015; 32:1884-93; PMID:25446772; http://dx.doi.org/10.1007/s11095-014-1582-1
-
(2015)
Pharm Res
, vol.32
, pp. 1884-1893
-
-
Sukumaran, S.1
Gadkar, K.2
Zhang, C.3
Bhakta, S.4
Liu, L.5
Xu, K.6
Raab, H.7
Yu, S.F.8
Mai, E.9
Fourie-O'Donohue, A.10
-
16
-
-
84992746178
-
-
http://www.lymepa.org/Antibiotics_spreadsheet_2004-1215.pdf
-
-
-
-
17
-
-
64549161964
-
Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy
-
19233622
-
F.C.Tenover, S.W.Sinner, R.E.Segal, V.Huang, S.S.Alexandre, J.E.McGowan, Jr, M.P.Weinstein. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int J Antimicrob Agents 2009; 33:564-8; PMID:19233622; http://dx.doi.org/10.1016/j.ijantimicag.2008.12.010
-
(2009)
Int J Antimicrob Agents
, vol.33
, pp. 564-568
-
-
Tenover, F.C.1
Sinner, S.W.2
Segal, R.E.3
Huang, V.4
Alexandre, S.S.5
McGowan, J.E.6
Weinstein, M.P.7
|